2019 reasons to bank cord blood?
That may sound like a lot, but it’s really very few. Over 40,000 umbilical cord blood stem cell treatments have now been performed worldwide. That means that 40,000 people, the majority of them children, have had their lives saved or enhanced by something that we routinely throw in the bin: the umbilical cord and placenta. Each of these patients has a story that amounts to a pretty good reason to protect your own family’s health.
More than 80 conditions can be treated with cord blood stem cells: Leukaemia, Neuroblastoma, Sickle Cell Disease, Type 1 Diabetes, Cerebral Palsy, Krabbe Disease… Each of these is a powerful reason to bank your baby’s cord blood stem cells.
What’s more, the Parents’ Guide to Cord Blood estimates that there are currently 114 open cord blood trials. These trials are exploring the potential of cord blood and umbilical tissue to treat Stroke, Lung Disease, Eye Sight, Infertility, Heart Disease… 114 more excellent reasons to invest in cord blood banking now.
40,000 treatments for 80 conditions and another 114 trials underway. That’s 40,194 good reasons to bank cord blood, or 110 for each day of 2019.
What to expect in umbilical cord banking
As a new year dawns things are looking bright for regenerative medicine. In 2018 we saw the work of scientists specialising in umbilical cord blood and tissue stem cells celebrated and nurtured with awards and grants; a new business established to protect families against the costs of stem cell treatment; the successful launch of World Cord Blood Day; and, more important than all of these things, in 2018 cord blood stem cells were used to treat a greater variety of diseases and conditions than ever before.
With new trials underway and exciting new research emerging it seems likely that 2018 will see more patients treated with cord blood stem cells than ever before, and for a wider range of conditions.
In 2019 it is also likely that Mesenchymal Stem Cells from umbilical tissue will emerge as therapeutically valuable, opening up a whole new area of treatment for diseases and conditions in which tissue cells such as bone, muscle and tendon have from suffered disease or injury.
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.